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ABSTRACT
Acute Radiation Syndrome (ARS) may lead to cancer and death and has few 
effective countermeasures. Efficacy of synthetic PIF treatment was demonstrated in 
preclinical autoimmune and transplantation models. PIF protected against inflammation 
and mortality following lethal irradiation in allogeneic bone marrow transplant (BMT) 
model. Herein, we demonstrate that PIF imparts comprehensive local and systemic 
protection against lethal and sub-lethal ARS in murine models. PIF treatment 2 h 
after lethal irradiation led to 100% survival and global hematopoietic recovery at  
2 weeks after therapy. At 24 h after irradiation PIF restored hematopoiesis in a semi-
allogeneic BMT model. PIF-preconditioning provided improved long-term engraftment. 
The direct effect of PIF on bone marrow cells was also demonstrated in vitro: PIF 
promoted pre-B cell differentiation and increased immunoregulatory properties of 
BM-derived mesenchymal stromal cells. PIF treatment also improved hematopoietic 
recovery and reduced systemic inflammatory cytokine production after sub-lethal 
radiation exposure. Here, PIF also prevented colonic crypt and basal membrane 
damage coupled with reduced nitric oxide synthetase (iNOS) and increased (B7h1) 
expression. Global upper GI gene pathway analysis revealed PIF’s involvement in 
protein-RNA interactions, mitochondrial oxidative pathways, and responses to cellular 
stress. Some effects may be attributed to PIF’s influence on macrophage differentiation 
and function. PIF demonstrated a regulatory effect on irradiated macrophages and 
on classically activated M1 macrophages, reducing inflammatory gene expression 
(iNOS, Cox2), promoting protective (Arg1) gene expression and inducing pro-tolerance 
cytokine secretion. Notably, synthetic PIF is stable for long-term field use. Overall, 
clinical investigation of PIF for comprehensive ARS protection is warranted. 
                   Research Paper
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INTRODUCTION
Acute radiation syndrome (ARS) is caused by 
high-dose whole or partial body radiation exposure 
[1, 2]. ARS may cause complete destruction of the bone 
marrow (BM), damage the mucosal barrier and crypts of 
the gastrointestinal (GI) tract, as well as skin burns and 
central nervous and cardiovascular system injury leading 
to irreversible neurological and cardiovascular damage 
and ultimately, death. In addition, the exposure to radiation 
can also increase the risk for development of cancer [3]. 
Radiation is particularly harmful to cells with rapid 
turnover such as those of the hematopoietic system and the 
gastrointestinal mucosa [2]. These injuries are associated 
with massive systemic inflammation and impaired 
immunity [2, 4–7].
Faced with the complexity of ionizing radiation 
induced injury, conventional ARS management lacks 
effective and comprehensive countermeasures. The 
current standard of care includes blood transfusion, fluid 
and electrolyte administration, antibiotic and antiviral 
therapy. Following low grade radiation, patients with 
cytopenia receive granulocyte colony-stimulating factor 
or granulocyte macrophage colony-stimulating factor 
to induce repopulation of the immune system from 
residual hematopoietic progenitor cells [4, 5, 7–9]. Non-
responders and patients exposed to lethal radiation require 
hematopoietic stem-cell transplantation (HSCT) [5, 7, 9]. 
Such transplantation frequently leads to deleterious graft 
vs. host disease (GVHD) [10]. Not surprisingly, placental 
stem cells, with reduced antigenicity, were tested for ARS 
therapy [11]. However, using human-derived cells raises 
concerns with respect to purity, preservation quality, 
appropriate availability, and ultimate efficacy. Several 
other countermeasures have been examined but they are 
not currently approved for clinical use [12–16].
Ideally, ARS management should comprehensively 
cover all levels of exposure to irradiation (lethal or sub-
lethal) both locally (colon, etc.) and systemically (i.e. 
hematopoietic, cytokines).
Pregnancy presents a unique immune environment 
wherein the embryo, a semi-allogeneic or allogeneic 
graft, is not rejected and does not lead to a graft vs. 
host response. Instead, pregnancy actually achieves 
ideal immune and transplant regulation. Therefore, the 
attributes of pregnancy could provide valuable guidance 
in the identification of effective and safe immuno-
modulatory molecules. PreImplantation Factor (PIF) is 
an embryo-secreted 15–amino acid peptide which has 
an essential role in promoting embryo implantation and 
placental engraftment [17–23]. PIF presence in embryo 
culture media, placental and maternal circulation, is 
associated with favorable pregnancy outcome [24, 25] 
whereas its absence correlates with lack of viability. 
Synthetic PIF maintains its immunoregulatory properties 
in non-pregnant clinically-relevant models [20, 26–28]. 
PIF is effective against hypoxic brain damage plus 
an array of autoimmunity models, including those 
of neurodegenerative diseases, juvenile diabetes and 
atherosclerosis [29–34]. Importantly, PIF prevented 
deleterious semi- allogeneic as well as allogeneic murine 
GVHD following irradiation conditioning and preserved 
the beneficial Graft versus Leukemia (GVL) effect [10]. 
The protective effect was correlated with decreased levels 
of pro-inflammatory cytokines, both locally in target 
organs, and systemically. 
Important mechanistic effects can explain the 
observed PIF induced protection in preclinical models. 
PIF directly regulates immune cell function by acting on 
macrophages and activated T cell proliferation, leading to 
a cytokine Th2 bias, as well as regulating NK cell activity 
[26, 28, 35]. In murine macrophages, PIF increased B7h1 
(ligated to PD-1 on T-cells) and decreased LPS-induced 
Nos2 gene (iNOS, nitric oxide synthase) expression [10]. 
In human immune cells PIF targets protein-di-isomerase/
thioredoxin (PDI/T) and heat shock proteins (HSPs) to 
reduce oxidative stress and protein misfolding [31, 32, 36]. 
PIF acts as a competitive inhibitor of cortisone binding 
to Kv1.3b where it reduces K+ ions release acting as a 
benign steroid [37]. Together, these in vitro and preclinical 
in-vivo results attest to PIF’s potential as a countermeasure 
for ARS. 
Herein, we examine PIF’s potential as a treatment 
for ARS. PIF is used as a single therapy, without 
antibiotics, to provide mechanistic insight. Clinically 
relevant ARS scenarios were investigated following lethal 
and sub-lethal total body irradiation in murine models. 
PIF’s effect on hematologic recovery when used alone, 
when combined with BMT, and when used for graft 
pre-conditioning was investigated. PIF’s direct effect on 
cultured BM was determined. PIF’s effect on systemic 
inflammation, local GI tract pathology, and global gene 
expression was tested. 
We report herein that PIF offers comprehensive 
protection against ARS in the murine model and warrants 
clinical testing in humans.
RESULTS 
PIF protects against mortality and restores 
hematopoiesis after lethal irradiation
Early diagnosis and intervention are critical for the 
survival of patients who have been exposed to a lethal dose 
of ionizing radiation. To determine whether PIF is effective 
for such rapid intervention we used C57BL/6 mice, a 
relatively radio-resistant strain [38]. PIF treatment was 
initiated 2 h after whole body lethal irradiation (8 Gy) and its 
effect on survival and long-term hematopoiesis was studied. 
Female mice (C57BL/6, n = 18 per group) were treated with 
low-dose (0.75 mg/kg) , high-dose PIF (1.25 mg/kg), or PBS 
control twice daily for 14 days, followed by 14 days of post-
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therapy monitoring (Figure 1A). Both PIF treatment groups 
had 100% survival until day 29, when they were sacrificed. 
In contrast, all the control mice (n = 14) developed ARS and 
had died by day 23 (0% survival) p < 0.0001 (Figure 1B). 
No significant differences were found between the two PIF 
doses tested. Figure 1C shows that mean white blood count 
(WBC) count was preserved on day 12, in both PIF-treated 
groups, as compared with the control group, which had a 
very low WBC count by that time. Remarkably, by day 29, 
WBC counts were restored to normal levels in both low 
and high-dose PIF treated mice. PIF also maintained the 
hematocrit levels throughout the experiment. In contrast, the 
control mice exhibited hematocrit levels of less than 10% by 
day 12 of the study (Figure 1D). Moreover, platelet counts in 
PIF treated mice remained high throughout the experiment. 
In contrast, in the PBS control group, platelet counts rapidly 
declined until day 12 and remained very low until demise of 
all mice. (Figure 1E). 
Figure 1: PIF enhances hematopoiesis after lethal irradiation. Mice were irradiated with 8 Gy. Two doses of   PIF treatment, 0.75 mg/kg 
(low dose) or 1.25 mg/kg (high dose), or PBS was administrated SQ 2x/day for 14 days starting 2h post irradiation. The protocol of 
the experiment is described in (A). Survival rate was monitored during 29 days post irradiation. The difference between the groups is 
significant. (p < 0.0001) (B). Blood count was compared: WBC (C), hematocrit (D), platelets (E) and different cell populations (F). No 
differences were found between pre-treatment and end of the experiments with respect to any hematologic index.
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PIF’s effect on the recovery of different WBC cell 
populations following lethal irradiation and low dose 
PIF administration is demonstrated in Figure 1F. The 
lymphocyte time course resembles the global WBC. 
Reciprocal effects were seen between neutrophil and 
lymphocyte counts, namely a decrease in lymphocytes 
was associated with an increase in neutrophils, while 
monocyte, eosinophil and basophil levels remained 
practically unchanged.
Notably, similar results were obtained with male 
C57BL/6 mice (Supplementary Figure S1). Thus, prompt 
PIF administration as single therapy following lethal 
radiation prevents mortality and maintains hematopoiesis 
after therapy. The attached video shows PIF treated mouse 
recovery after lethal ARS (VIDEO Supplement). 
PIF treatment after lethal irradiation followed 
by semi-allogeneic bone marrow transplantation 
promotes transplant engraftment
Optimally, ARS therapy should be administered 
shortly after lethal irradiation (for prophylaxis) as 
above. However, therapy is frequently delayed due to 
inaccessibility and subsequently HSCT may be required. 
Since the donor must be available on short notice, haplo-
identical allogeneic transplantation may be the only 
option. It was previously reported that PIF prevents 
GVHD development (skin ulceration, hepatitis and colon 
ulceration) after allogeneic bone marrow transplantation 
(BMT) [10, 39]. Whether PIF also promoted hematopoietic 
engraftment to restore immune profile critical for survival 
had not been determined. 
The present study therefore examined PIF’s effect 
on hematologic recovery after lethal total body irradiation 
followed by semi-allogeneic transplantation (a model for 
haplo-identical transplant). In order to mimic a clinical 
scenario where access to care is not immediately available 
after exposure, PIF administration was delayed 24 h post 
exposure. F1 (C57BL/6 xBalb/c) mice were exposed to 
10 Gy total body irradiation. On the next day the mice 
were transplanted with C57BL/6 BM by intravenous 
(IV) administration. PIF (1 mg/kg/day) or PBS was 
administered continuously starting at 24 h post-irradiation, 
for 2 weeks, using an Alzet osmotic pump (Figure 2A). 
Clinical condition and hematologic recovery were 
monitored for 4 weeks post-irradiation. It was observed 
that PIF-treated, compared to PBS-treated, mice showed 
significantly increased recovery of total systemic WBCs 
at 3 weeks post-transplantation, (Figure 2B). In addition, 
PIF treatment also improved the lymphocyte/granulocyte 
ratio when compared to PBS control mice (Figure 2C). 
At 4 weeks after transplant femoral bone histology was 
performed. Representative histologic images of femoral 
bone marrow of normal, PBS and PIF treated mice are 
presented in Figure 2D–2F, respectively. The fat cell 
number (index of the bone marrow reservoir) in the PIF 
treated group was significantly lower than that of the 
PBS treated mice (Figure 2G), demonstrating improved 
rehabilitation. Remarkably, fat cell number following 
PIF treatment was not significantly different from that of 
normal mice. Thus PIF, after lethal irradiation and BMT, 
rapidly restores both the circulating and the bone marrow 
hematopoietic reservoir.
Transplantation of PIF preconditioned 
allogeneic bone marrow enhances hematologic 
reconstitution following lethal irradiation, 
without additional therapy
PIF’s effect on the immune response was 
demonstrated in several previous publications [10, 26–28, 
31, 32]. The above data documented PIF’s ability to 
promote hematologic recovery following BMT. Whether 
PIF’s effect is direct or indirect on bone marrow (BM) 
cells is unknown. 
To address this question, donor BM cells were pre-
incubated with PIF in culture for 2 h. The cells were then 
washed prior to transplant. Recipient mice were lethally 
irradiated (10 Gy) and 24 h later the pre-conditioned 
allogeneic BM was transplanted. No additional treatment 
was administered throughout the 4 week monitoring 
period. The experimental protocol and plan are sketched 
in Figure 3A.
Although the BM was incubated with PIF for only 2 h 
prior to transplantation, its pre-conditioning significantly 
improved total WBC count, and, particularly, lymphocyte 
count, at 3 and 4 weeks post-transplant (Figure 3B and 
3C, respectively). Improved engraftment was coupled 
with improved femoral bone marrow cellularity at 4 weeks 
(Figure 3D–3F). Thus, PIF pre-incubation alone leads 
to effective engraftment of BM cells without requiring 
further therapy post-transplant; this indicates a direct 
effect of PIF on the grafted cells.
PIF exerts a direct effect on BM cells function  
in vitro
To elucidate PIF’s direct regulation of BM cells, its 
effect in-vitro was examined. First, we used MethoCult 
M3630 medium to differentiate pre-B cells from C57BL/6 
mice BM progenitor/stem cells. In this experiment, 2 h 
PIF pre-incubated BM cells were compared with BM cells 
cultured in the presence of PIF or PBS (control) within 
the media (Figure 4A and 4B). The colonies formed 
were photographed and then the cells were harvested 
and counted. Following PIF exposure, with either pre-
incubated cells or with cells cultured with PIF, larger 
colonies of pre-B cells were present (Figure 4A) and 
significantly higher B-cell counts were observed as well. 
(Figure 4B).
Another important cell population of BM are 
mesenchymal stromal cells (MSCs). These are multipotent 
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progenitor cells which exert powerful anti-inflammatory 
and immuno-suppressive functions. Since we have already 
demonstrated PIF’s immune modulatory properties in a 
variety of cells, its effects on the regulatory function of 
MSCs derived from C57BL/6 mice was next examined. 
MSCs were preconditioned with PIF for 2 h, washed, and 
then co-cultured with CFSE stained C57BL/6 splenocytes, 
activated with anti-CD3-antibody. The percentage of 
proliferating cells, as compared to activated splenocytes 
without MSCs, was determined by FACS analysis. The 
PIF-treated MSCs exerted a significant suppressive effect 
on splenocyte proliferation (65% inhibition) as compared 
to that of PBS control cells (50% inhibition) (Figure 4C). 
PIF added to the MSC culture also promoted secretion of 
Figure 2: PIF improves hematopoiesis after lethal irradiation and semi-allogeneic BMT. Mice were irradiated with 10 Gy 
followed by semi-allogeneic BMT. 1 mg/kg/day PIF or PBS were administered continuously for 2 w starting 24 h after irradiation. The 
protocol of the experiments is described in (A). WBC count 3 w after irradiation and transplantation (B). The percentage of lymphocytes 
and granulocytes 3 w post irradiation (C). Histological examination of the femur for cellularity level of BM in normal (D), PBS (E) 
and PIF treated mice (F). Fat cell number in 0.75 mm2 section of femur BM is a summary of 2 independent experiments (G). *p < 0.05, 
****p < 0.001.
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pro-tolerance TGFβ and IL10 cytokines, both in a dose-
dependent manner (Figure 4D).
These data demonstrate that PIF exerts a dual effect 
on transplanted cells, by promoting differentiation and by 
immune regulation.
PIF alone promotes hematologic recovery at 24 h 
following sub-lethal irradiation dose
The data above showed that early PIF administration 
protects against lethal ARS and is also effective after 24 h 
when combined with BMT. Next, the efficacy of PIF as a 
sole agent administered at 24 h after sub-lethal irradiation 
was examined. PIF (1 mg/kg/day) or PBS (control) were 
administered continuously (0.25 ml/h) for 2 weeks, starting 
at 24 h after 6 Gy irradiation. The radiation dose was 
chosen based on a radiation survival curve (Supplementary 
Figure S2). The clinical status and hematologic recovery 
were monitored for 4 weeks after irradiation. The 
experimental protocol and plan are sketched in Figure 5A. 
PIF aided in rapid recovery and significantly improved 
the reconstitution of circulating WBCs in comparison 
with PBS treated mice (Figure 5B). Two weeks post-
irradiation, the mean WBC count was 600 cells/µl 
Figure 3: PIF pretreated BM enhances hematologic recovery after lethal irradiation and allogeneic BMT Donor BM 
cells were incubated with PIF for 2 h prior to transplantation. Mice were irradiated with 10 Gy followed by allogeneic BMT 
with the pretreated BM graft. No additional treatment was given to the mice. The protocol of the experiments is described in (A). WBC and 
lymphocyte counts at 3 w (B) and 4 w (C) after irradiation and transplantation. Histological examination of the femur for cellularity level 
of the BM in normal (D), PBS (E) and PIF treated mice (F). Results represent 3 independent experiments. *p < 0.05.
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in PIF-treated mice as opposed to 250 cells/µl in PBS 
treated mice, reflecting improved recovery. The same trend 
was also evident at 4 weeks post-irradiation (Figure 5C). 
Moreover, at 2 weeks after its administration, PIF 
normalized the lymphocyte/granulocyte ratio by increasing 
lymphocyte percentage while reducing granulocyte 
percentage (Figure 5D). In contrast, in PBS treated mice, 
an elevated granulocyte percentage was noted, reflecting 
an enhanced inflammatory response. Thus, PIF treatment 
restores the immune profile after sub-lethal irradiation.
PIF reduces circulating pro-inflammatory 
cytokine levels after sub-lethal irradiation
Inflammation and its associated circulating 
inflammatory cytokines contribute to ARS pathology. 
The effect of PIF on systemic inflammatory response 
was therefore examined. 24 h following 6 Gy total body 
irradiation, subcutaneous 0.75 mg/kg PIF or PBS was 
administered twice daily for three days (Figure 6A). 
Serum samples were collected for cytokine measurement.
Circulating levels of the pro-inflammatory 
cytokines, IL1α and IL2, were significantly decreased 
in PIF treated mice (Figure 6B). The effects on other 
cytokine levels (such as TNFα, GMCSF, IL10, IL4, and 
IL17) were below the limits of detection. These results 
imply that PIF administration after sub-lethal irradiation 
is effective in reducing systemic inflammation.
PIF promotes regulatory macrophage 
differentiation
PIF’s immune-modulatory effect on monocytes 
was previously demonstrated [10, 27, 40]. Activated 
macrophages secrete pro-inflammatory cytokines which 
can then contribute to ARS pathology, as demonstrated 
Figure 4: PIF improves pre-B cell differentiation from BM and enhances immunoregulatory function of MSC. 2 h PIF 
pre-treated BM cells (middle), BM cells that were differentiated in the presence of PIF in the medium (right), and control PBS treated 
cells (left) were differentiated to pre-B cells in MetoCult M3630 differentiation medium (A and B). Pictures of representative colonies are 
represented in A and number of cells/well from 3 independent experiments in B. Inhibition of activated murine splenocyte proliferation 
by MSC and 2 h PIF pre-treated MSC, CFSE experiment (C). PIF effect on cytokine secretion from MSC, ELISA (D). Results represent 
3 independent experiments. *p < 0.05.
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above (Figure 6B). To test the direct effect of PIF on 
activated macrophages, we examined PIF’s protection 
against radiation-induced damage in macrophage culture.
Following 5 Gy irradiation of RAW 264.7 
macrophages, 200 nM PIF was added to the culture and 
its effect on the cytokine profile was determined. We 
focused on TNFα, IL-6, and IL-10 cytokines since they 
have been previously demonstrated to be affected by 
ionizing radiation [41]. PIF reduced TNF-α and IL-6 pro-
inflammatory cytokine secretion while promoting IL-10 
regulatory cytokine secretion. (Figure 7A). RT-PCR of the 
irradiated macrophages confirmed this inhibitory effect on 
TNF-α expression (data not shown). 
Macrophages, as key mediators of the immune 
response, can differentiate into classically activated 
inflammatory macrophages (M1) or into alternative 
activated regulatory macrophages (M2). GM-CSF is 
reported to increase oxidative stress gene expression 
leading to pro-inflammatory macrophage M1 polarization. 
[42] We have previously demonstrated that PIF induces 
reduction of iNOS gene expression in the GVHD model 
[9]. Since iNOS is one of the inflammatory M1 macrophage 
hallmarks, we analyzed the influence of PIF on 
macrophage differentiation. Peritoneal macrophages were 
obtained from C57BL/6 mice and differentiated in culture 
towards M1/M2 phenotypes in the presence/absence of 
Figure 5: PIF enhances hematologic recovery after sub-lethal irradiation. Mice were irradiated with 6 Gy. 1 mg/kg/day PIF 
or PBS was administrated continuously for 2 w starting 24 h after irradiation. The protocol of the experiments is described in (A). Follow-
up of WBC reconstitution of the irradiated mice (B). WBC counts 2 and 4 w post irradiation (C). The percentage of lymphocytes and 
granulocytes 4 week post irradiation (D). Results represent 2–3 independent experiments. *p < 0.05, **p < 0.01.
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PIF (Supplementary Figure S3). In M1 macrophages PIF 
significantly decreased the levels both iNOS and COX-2 
gene expression (Figure 7B and 7C, respectively) and 
enhanced the expression of arginase, which is a marker 
of M2 regulatory macrophages (Figure 7D). Collectively, 
these results suggest that PIF regulates macrophage 
differentiation.
PIF promotes colonic crypt and architecture 
recovery and regulates gene expression in the GI 
tract following sub-lethal irradiation
Since PIF reduced systemic inflammation by 
decreasing pro-inflammatory cytokines, we examined 
whether this was also coupled with local GI protection, 
a key element in early ARS, and where inflammation and 
injury are common [2, 6, 7]. PIF’s ability to reduce colonic 
ulceration and liver inflammation in a murine GVHD 
model after lethal irradiation was previously noted [10]. 
Herein, mice were exposed to 6 Gy total body irradiation 
and then treated with subcutaneous 0.75 mg/kg PIF or 
PBS for 3 or 2 days, starting 24 or 48 h post-irradiation, 
respectively Figure 6A. GI tissue samples were harvested 
for analysis. 
H&E staining showed that PIF significantly 
reduced colonic inflammation and restored colonic 
crypt morphology and colonic architecture even when 
PIF administration was delayed. In contrast, in PBS 
treated mice the colonic basal membrane became very 
thin, the colonic serosa was almost absent, and the 
intra-colonic architecture was completely disrupted 
(Figure 8A). Moreover, colonic crypt depth in PIF-treated 
irradiated mice was similar to that seen in normal mice 
and significantly different from that of the control mice 
(Figure 8B). 
Colon genome analysis by real-time PCR also 
showed that PIF reduces iNOS gene expression as 
compared to the PBS control group (Figure 8C). Moreover, 
the expression of B7H1 in the colon of PIF treated mice 
was significantly up-regulated (Figure 8D). Therefore, 
PIF treatment reverses colonic inflammation even when 
administered up to 48 h after irradiation exposure.
The significant protective activity derived from 
PIF function was further examined by analyzing GI 
tract global gene expression using the Illumina array. A 
heatmap was created where the color scale indicated the 
relative rank of a pathway in a given comparison, with 1.0 
meaning top rank and 0.0 meaning that a pathway was not 
Figure 6: PIF reduces systemic inflammation after sub-lethal irradiation. Mice were irradiated with 6 Gy. 0.75 mg/kg PIF or 
PBS were administered SQ 2x/day for 3 days, starting at 24 h after irradiation. The protocol of the experiments is described in (A). Levels 
of IL-1α and IL-2 in the serum of experimental mice were measured by FlowCytomix Multiplex kit (B). *p < 0.05.
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significant. As shown in the heatmap analysis (Figure 9A), 
several affected pathways were detected when comparing 
the different sample groups (see Tables 1, 2 for ranking). 
The data were also used to draw an illustration of 
the network of genes affected by PIF treatment. This 
detailed network analysis of the relationship between the 
most important pathways (gene sets) for the irradiation 
plus PIF treatment versus irradiation treatment alone 
showed a clustering of gene sets into three main groups: 
genes involved in protein-RNA interactions, genes for 
mitochondrial functions related to oxidative pathways, and 
genes related to the response to cellular stress (Figure 9B). 
The top 20 genes, whose expression are up- or down-
regulated by PIF in the GI tract as compared with PBS, 
are shown in Supplementary Table S1 and S2. The data 
generated confirm that the protection against ARS involves 
regulation of the inflammatory process whereas protection 
against ionizing radiation is coupled with metabolic and 
immune repair mechanisms. 
PIF is highly stable and fit for rapid 
administration
The utility of a drug is based on its availability and 
convenience of use in an adverse environment. To further 
establish PIF’s durability, stability testing was carried out 
by using HPLC and mass spectrometric analysis of clinical 
grade synthetic PIF. After 8 weeks of storage at ambient 
temperature, PIF’s clinical grade quality was maintained, 
making it suitable for field use ( Supplementary Table S3). 
Thus PIF is suitable for prompt use in the field, where 
accidental or deliberate exposure to radiation may occur. 
Figure 7: PIF promotes TH2/TH1 bias following irradiation and shifts M1 macrophage differentiation to M2-like 
phenotype. (A) The RAW 264.7 macrophage cell line was employed in this study. The cells were irradiated (5 Gy) in the presence and 
absence of PIF (200 nM)- PIF reduced TNF- and IL6 while promoting IL10 secretion. Representative of 3 independent experiments. 
*p < 0.01. (B) Peritoneal macrophages were cultured with GM-CSF (10 ng/ml) and LPS (10 ng/ml) for M1 differentiation or with M-CSF 
(10 ng/ml) and IL-4 (10 ng/ml) for M2 differentiation for 20 h in the presence/absence of sPIF. qPCR analysis of iNOS (A) COX-2 (B) and 
Arginase (C) mRNA expression of the differentiated cells. % of M1 macrophages gMFI of F480 (D) and CD11b (E) by FACS analysis. 
Results represent 5–6 independent experiments. *p < 0.05, **p < 0.01 ****p < 0.001.
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DISCUSSION
ARS due to total body irradiation leads to local and 
systemic inflammation followed by long-term hematologic 
failure and organ damage. Despite ongoing efforts, 
current therapies are of limited efficacy and most often 
are associated with significant risks. There are no new 
approved drugs that would comprehensively address ARS. 
The major finding in this study is that PIF, administered 
as a single therapy, accomplishes this comprehensive ARS 
treatment capability, covering the spectrum of the disease. 
ARS is a complex disease which can affect 
practically any organ in the body. The degree of radiation 
damage is related to dose, duration, whether exposure 
is total or targeted to only a selected organ, and it also 
importantly depends on the host’s susceptibility. The aim 
of this study was to comprehensively cover possible ARS 
scenarios, both short and long-term consequences, and 
with a clear connotation for future clinical translation.
Endogenously secreted, PIF, due to its embryo-
derived origin and function, plays an essential role in 
the maternal recognition of pregnancy that is, protecting 
the embryo/allograft against rejection while achieving 
maternal/host tolerance through immune modulation 
(but not immune suppression) [34]. Synthetic PIF 
administration was previously shown to duplicate the 
pregnancy-observed global immune and transplant 
regulatory effects of native PIF, and presents the 
qualities needed to address the ARS spectrum of disease. 
Observations in both in vitro and in clinically relevant 
preclinical models support the view that PIF therapy 
could be useful as a comprehensive local and systemic 
countermeasure against ARS. PIF was found to preserve 
local GI homeostasis, restore bone marrow cellularity 
and improve systemic hematopoiesis. This protective 
effect is further potentiated by a macrophage shift, from 
inflammatory to regulatory type, combined with reduced 
circulating pro-inflammatory cytokines. 
PIF administration immediately after exposure 
to lethal radiation provides a rapid and comprehensive 
response to accidental (i.e. nuclear power plant) or 
medical (radiation oncology) exposure. Importantly, 
immediate PIF treatment (within 2 h of irradiation) 
protects against high-dose radiation mortality, preserving 
Figure 8: PIF treatment provides local colon protection after sub-lethal irradiation. Mice were irradiated with 6 Gy. 24 
or 48 h post irradiation mice were treated subcutaneously with 0.75 mg/kg PIF twice a day for 72 or 48 h, respectively. Histological 
examination of the colon at four days after irradiation (A). Statistical analysis of the colonic crypt depth of the different groups (B). qPCR 
analysis of iNOS (C) and B7H1 (D) mRNA expression in the colon. Results represent 2 independent experiments. *p < 0.05, **p < 0.01.
Oncotarget58986www.impactjournals.com/oncotarget
blood indices without any additional therapy. At no point 
was significant reduction in hematocrit or platelet count 
was noted, while WBC levels oscillated but did not reach 
immune suppressive levels. Comparable protective effects 
on both female and male mice, coupled with the normal 
endogenous exposure to PIF in all offspring throughout 
pregnancy, supports a gender independent clinical 
application potential for ARS therapy.
In cases of deliberate exposure, the treatment is 
delayed until victims are brought to medical care facilities. 
In both sub-lethal irradiation as well as in lethal irradiation 
circumstances followed by BMT, PIF was shown to impart 
an effective and comprehensive treatment for radiation 
injuries, even when administration was initiated 24–48 hrs 
post-irradiation. Currently HSCT is the mainstay for 
long-term management of lethal ARS when immediate 
intervention is not available. However, HSCT can be 
difficult to arrange on a short notice since donor-matching 
and availability is complex. Therefore, the ability to 
transplant without complete matching remains a major 
Figure 9: Heatmap analysis of the global GI genome. Pathways analysis results of the RNA array data. The color scale indicates 
the relative rank of pathway in a given comparison, with 1.0 meaning top rank and 0.0 indicating a pathway that was not found significant 
at all (A). Gene sets for radiation exposure of the different treatments (PIF, PBS or normal mice). Every node represents a gene set. The 
size of a node reflects the number of genes in a gene set; node color reflects the significance (corrected p-value) with lower p-values with 
a red color (B). Edges denote overlap (i.e. 1 or more shared genes) between 2 gene sets. The width of an edge reflects the relative size of 
the intersection (Jaccard similarity) compared to both gene sets. Edges pointed one way denote relationships where subtracting 1 gene set 
from a second reduces the significance of the latter. In this case, the arrow points towards the more significant gene set. Bidirectional edges 
indicate subset relations; double lines indicate cases where the significance of both gene sets is solely due to the intersection between these.
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challenge. We have previously reported that following 
allogeneic BMT, PIF administration led to reduced 
morbidity and mortality [10]. Herein we demonstrated that 
PIF, through a short 2 hour preconditioning of the BM, 
improves hematopoietic recovery after semi-allogeneic 
BMT without further therapy, indicating a direct regulatory 
effect of PIF on BM cells. Such an approach may positively 
impact both ARS and HSCT management. Together with 
previously reported data demonstrating the beneficial effect 
of PIF treatment on GVHD [10], PIF treatment may offer a 
long-term solution for allogeneic BMT patients. 
The direct effect of PIF on BM cells was also 
demonstrated in vitro, by improved differentiation of 
pre-B cells in culture, reduced adverse immune activation 
and enhanced pro-tolerance cytokine secretion of PIF 
treated MSCs. Thus, the mechanism of PIF protection in 
ARS probably includes both immune-modulatory effects 
(as demonstrated in several of our previous publications, 
[26, 27, 40] as well as in our present results), and direct 
effects on bone marrow cells. 
Exposure to sub-lethal irradiation may cause 
severe chronic damage from secondary complications. 
Such exposure damages hematopoiesis, and causes both 
systemic as well as local inflammation. PIF increases the 
lymphocyte/neutrophil ratio after sub-lethal irradiation; 
this persisted weeks after stopping therapy, providing a 
long term therapeutic solution. The systemic inflammatory 
response is rapid, aggravating ARS by promoting pro-
inflammatory cytokine increase. The PIF-induced 
reduction of circulating IL-2 and IL-1α to levels seen in 
healthy mice indicated lowered systemic inflammation. 
IL-2 is a prime stimulator of the adaptive immune response 
and its activation shortly after exposure would be clearly 
detrimental. IL-1α is a pro-inflammatory cytokine that is 
released by macrophages and acts in synergy to stimulate 
IL-2 secretion. Indeed, PIF enhanced pro-tolerance 
cytokine secretion in radiation treated macrophages, 
providing direct evidence for targeted protection. M1 
macrophages are pro-inflammatory and have a central role 
in host defense against infection, while M2 macrophages 
are associated with responses to anti-inflammatory 
reactions and tissue remodeling. M1-M2 macrophages 
represent two distinct directions within the full 
spectrum of macrophage activation. We have previously 
demonstrated that PIF binds to monocytes leading to 
their differentiation to an immune-regulatory type [10]. 
Additionally, down-regulation of iNOS, gene expression, 
a M1 macrophage hallmark, was evident in target organs 
of PIF treated mice in both the current ARS model and 
in our previous GVHD model [10]. In this study, the 
addition of PIF to M1 macrophages reduced the M1 
phenotype by decreasing the levels of iNOS and COX-2 
gene expression. In macrophages that express iNOS, the 
level of COX-2 expression is an important indicator of 
the degree of inflammation [43]. Thus PIF-associated 
decreases in iNOS and COX-2 expression correlate with 
decreased serum levels of IL1α and colonic iNOS gene 
expression, as observed in our in-vivo model.
Table 1: Ranking pathways involved in PIF action based on global GI gene analysis: comparison 
PIF to PBS – control
Control PIF Biological Process Description 
1 2.432692308 GO:0006979 response to oxidative stress
0.990384615 2.476934997 ITFP:Eif4a1 Eif4a1 targets
0.980769231 1.245192308 GO:0005198 structural molecule activity
0.971153846 1.242788462 GO:0016477 cell migration
0.961538462 1.240384615 GO:0035257 nuclear hormone receptor binding
0.951923077 1.237980769 ITFP:Lman1 Lman1 targets
0.942307692 1.235576923 GO:0031735 CCR10 chemokine receptor binding
0.932692308 1.233173077 WP295 Electron Transport Chain
0.923076923 1.230769231 GO:0044455 mitochondrial membrane part
0.913461538 1.228365385 5893258 Respiratory electron transport, ATP synthesis by 
chemiosmotic coupling
0.903846154 1.225961538 GO:0001085 RNA polymerase II transcription factor binding
0.894230769 1.223557692 ITFP:Sel1l Sel1l targets
0.884615385 1.221153846 5893543 eNOS activation and regulation
0.875 1.21875 GO:0046329 negative regulation of JNK cascade
PIF effect on gene pathway ranking in global GI genome was determined and compared with PBS (vehicle) treated mice 
exposed to sub-lethal- 600 rads. Following sacrifice the tissue mRNA was extracted and ran on an Illumina chip. (N = 7/group) 
Data generated were analyzed, determining strength of association of a pathway affected by PIF. Further details are described 
in the method section.
Oncotarget58988www.impactjournals.com/oncotarget
The GI tract has significant metabolic functions 
beyond digestion and electrolyte balance. It keeps 
the local micro-organism flora in check, and also 
serves primordially as an immune organ. Localized GI 
inflammation leads to cytokine release which activates 
systemic immunity. Since the colon has a rapid cellular 
turnover it is specifically sensitive to apoptosis and 
reduction in local stem cell function as a result of radiation 
[2, 44]. ARS-induced GI tract damage can therefore 
severely impact patient prognosis, leading to diarrhea, 
dehydration, and infection due to the altered bowel flora 
and function. Therefore, in order for a given therapy to be 
effective, both local and systemic compartments have to 
be effectively controlled. 
Remarkably, even at 48 hrs after sub-lethal 
irradiation and with only a 2 day administration, PIF 
protected against colonic inflammation and preserved 
normal colonic crypt depth and length values. By 
preserving basal membrane integrity PIF prevents 
diffusion of toxins, which may activate a systemic 
inflammatory response, from the colon. B7h1 is a key 
molecule involved in protecting the colon against 
inflammation, a function demonstrated with B7h1-knock-
out mice which develop severe chemically-induced colitis 
[45]. We previously demonstrated that PIF up-regulates 
B7h1 expression in macrophages which may negatively 
regulate T cell activation through association with the 
PD-1 ligand [10]. Herein, the decrease in iNOS and 
Nosip gene expression in the GI tract, combined with 
increased expression of the B7h1gene promotes local 
immune protection. Therefore, PIF could be hypothesized 
to also be useful for treatment of colon inflammation or 
ulceration, unrelated to ARS therapy. 
Global genome analysis, coupled with the heatmap 
analysis, provides a comprehensive insight into PIF 
protection of the GI tract. The PIF-induced effect was 
compared to both vehicle treated control and to healthy 
mice. One of the pivotal mechanisms to generate 
proteome diversity and complexity is alternative pre-
mRNA splicing where aberrant splicing predisposes to 
chronic inflammation [44, 46]. The Hnrpab pathway 
was used also to demonstrate PIF-induced protection in 
neural and immune cells [30, 47]. In the current model 
of ARS, the mitochondrial gene cluster, which PIF 
affects, involves regulators of reactive oxygen radicals 
and intracellular Ca2+ signaling molecules. This effect 
is relevant in inflammation control [45, 48], and in PIF-
induced promotion of neural cell survival [30, 47, 49–51]. 
Moreover, PIF was shown to regulate immune gene 
clusters and proteins [10, 31, 32]. Beyond the increase 
in the critical B7H1 gene (colon), PIF also reduced 
Panx1, involved in inflammasome activation,* and 
Cxcl13 expression,* which affects B-cell chemotaxis to 
Peyer patches. PIF also increased Olfactomedin4, Csp6 
and Lysozyme1 expression. Casp6 acts as executioner 
caspase and is likely to prevent GI cell apoptosis, while 
the increased Lysozyme1 expression can prevent infection 
and inflammation development. PIF may also influence 
the potential oncogenic propensity of the GI tract by 
regulating Ccnd, a cyclin dependent protein serine kinase 
[52, 53]. The role of all genes regulated by PIF is the basis 
of further investigation. 
Several agents have been evaluated for ARS therapy 
following lethal and sub-lethal irradiation exposure. 
Current interventions are mainly supportive, or involve 
hematopoiesis inducing agents like GM-CSF and, as 
recently suggested, IL-12, P selectin antibody, MSCs, and 
TLR ligands [12–14]. Specifically MSC action appears to 
be dependent on reducing the IL-17 inducing signaling in 
the colon [15]. Recently high-dose intraperitoneal TP508 
peptide injection protected against GI inflammation at 
24 h post-lethal radiation, reducing mouse mortality by 
30% and increasing survival from, on average 12.4 to 
16.8 days. As the authors stated, for long-term survival, 
additional life-saving medical treatment (i.e. BMT) is 
needed and is to remain as part of the solution [16]. 
The representative murine model used in the 
present study demonstrates that PIF comprehensively 
addresses the spectrum of ARS clinical scenarios, from 
lethal irradiation to sub-lethal exposure, with immediate 
or delayed administration, and from acute to chronic 
manifestations of the disease. Even when early treatment 
is unavailable and BMT becomes inevitable, PIF treatment 
or PIF BM pre-conditioning potentially offer a novel 
Table 2: Specific GI genes affected in the different pathways—comparison of PIF to PBS treated mice 
PIF effect on the individual genes of the global GI genome was determined and compared with PBS (vehicle) treated mice after 24 hours exposure to sub-
lethal- 600 rads. Following sacrifice, the tissue mRNA was extracted and ran on an Illumina chip. (N = 7/group). Data generated were analyzed, *determining 
association of a given pathway with genes affected by PIF. (Heatmap analysis)- figure 8. Further details are described in the methods section. 
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long-term solution for lethal irradiation management. 
PIF therapy is shown to prevent systemic inflammation, 
to provide long-term hematopoietic reconstitution and to 
restore GI tract functionality. 
Ease and accessibility of treatment is essential 
for effective ARS management. PIF is stable even after 
8 weeks at ambient temperature and therefore is highly 
utilitarian for both military or civilian needs. In addition 
to ARS, PIF may be considered as a therapy in other 
radiation induced syndromes. For example, radiotherapy 
is an important component in breast cancer treatment 
as it reduces recurrence and improves overall survival. 
However, such treatment raises the risk of acute and 
chronic side effects including radiation pneumonitis (RP), 
an early inflammatory reaction that occurs four to twelve 
weeks after completion of thoracic irradiation [54]. Our 
current results support the efficacy of PIF in reducing 
local irradiation induced inflammation, which is relevant 
for RP patients as well as for patients suffering from other 
radiotherapy induced complications. 
The efficacy of PIF observed in the current murine 
ARS model is valuable for translation to clinical testing. 
Importantly, PIF’s safety was demonstrated. PIF treatment 
is currently being tested in an ongoing University-
sponsored, FDA Fast-Track approved clinical trial for 
an autoimmune disease manifested in liver inflammation 
(NCT02239562). Therefore following this Phase I safety 
trial PIF could be also tested for the mitigation of radiation 
induced injury.
MATERIALS AND METHODS
Mice
The lethal 8 Gy ARS study was conducted under 
ethical conditions approved by the IACUC NIH OLAW 
(A4475-01), U.S. Dept. of Agriculture (USDA) and carried 
out by the BATTS Laboratory (Northridge CA). All the 
subsequent studies were done at the Hebrew University 
of Jerusalem (Israel) and approved by the Institutional 
Animal Welfare Committee (Israel). C57BL/6 mice (6–7 
or 8–9 w) and F1 (C57BL/6xBalb/c) mice (10–11 week 
old female) were obtained from Jackson Labs (Maine) 
and Harlan Laboratories, Ltd. (Israel), respectively. All 
mice were kept in pathogen free cages and housed under 
specific pathogen-free (SPF) conditions with a twelve-
hour light cycle. No antibiotics were administered.
PIF synthesis and administration
Synthetic PIF (MVRIKPGSANKPSDD) was 
obtained from Biosynthesis, Lewisville, NJ USA. All 
peptides were purified to > 95% purity, documented by 
mass spectrometry before being tested.
PIF peptide was dissolved in Dulbecco’s phosphate-
buffered saline (PBS) with 0.2% Dimethyl sulfoxide 
(DMSO) (Biological Industries and SIGMA, respectively). 
0.75 mg/kg or 1.25 mg/kg PIF was injected twice a day, 
SQ, for 14 days. For hematopoietic recovery studies in 
lethal irradiation+BMT and in sub-lethal studies, 1 mg/
kg/day PIF or PBS was administered continuously (0.25 
ml/h) starting one day post-irradiation and for 2 w,* using 
Alzet osmotic pumps (Model 1002, Durect Corp., CA), 
implanted SQ [10]. 
ARS Models: PIF therapy without BMT
C57BL/6 mice underwent lethal whole-body 
irradiation by single exposure to 8 Gy (BATTS laboratory) 
or sub-lethal whole-body irradiation by single exposure to 
6 Gy (Hadassah Hebrew U). The survival curve 6–10 Gy is 
shown (Supplement) All mice were irradiated with gamma 
radiation at a dose rate of 0.3 Gy/min. To minimize stress, 
no anesthesia was used enabling mice to move freely in 
the cage assuring uniform radiation exposure.
PIF therapy with BMT
F1 mice underwent lethal whole-body irradiation by 
single exposure to 10 Gy (Hadassah Hebrew U). One day 
post-irradiation, BM mononuclear cells from C57BL/6 
donor mice were collected by flushing the femur and 
tibia with PBS (Biological Industries). Mononuclear cells 
were isolated using Lymphoprep. 8 × 106 BM cells were 
administered through the tail vein of irradiated recipient 
mice. In another set of experiments, BM cells were pre-
incubated with PIF for 2 h before transplantation.
Clinical examination and complete blood count 
(CBC)
Following radiation exposure, mice were monitored 
daily for weight loss, ruffled skin, and survival. Blood 
was collected, according to the protocols, from the 
retro-orbital region or from the tail (BATTS Laboratory 
or Hadassah Hebrew University, respectively) into 
Ethylenediaminetetraacetic acid (EDTA) coated capillary 
tubes. CBCs with differentials were performed using 
a validated BC-2800Vet Auto Hematology Analyzer 
(Mindray).
B cell proliferation
BM cells obtained from C57BL/6 mice were incubated 
(2 h) with PIF or control prior to use. In some samples PIF 
was washed before culture. Cells were suspended in 200 ul 
IMDM (2% FBS) and then mixed with 2 ml of MethoCult 
M3630 (Stem Cell Technologies). The cells were then 
cultured (250 ul/well in 24 well plates) for 7 days.
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Mesenchymal stromal cell (MSC) experiments
Mouse MSCs were cultured from BM as previously 
described [55]. BM cells obtained from C57BL/6 mice 
were cultured in Mesencult basal medium supplemented 
with MSC stimulatory supplements (Stem Cell 
Technologies), at 37ºC with 10% CO2. After two to 
three passages, the cells were harvested and CD11b+ 
cells were depleted by EasySep cell separation kit (Stem 
Cell Technologies). After two more weeks in culture 
the phenotype of the cells was determined using Flow 
Cytometry. For the experiments, MSCs were incubated 
(2 hrs) with PIF or control prior to use in co-culture with 
activated splenocytes. CFSE (Thermo Fischer Scientific) 
stained murine splenocytes were activated with anti-CD3 
antibodies, (Pharmigen) for four days in co-culture with 
MSC (in a 1:50 ratio). Cell proliferation was analyzed 
using Flow Cytometry.
MSC cytokine secretion
The levels of IL-10 and TGFβ in the supernatants 
from cultures of PIF/PBS treated mouse MSCs were 
analyzed by enzyme-linked immunosorbent assay 
(ELISA) kits according to the manufacturer’s instructions 
(Thermo Fisher Scientific). The experiments were 
performed in triplicates to ensure reproducibility.
Histological analysis
Colon and femur samples were obtained from mice 
and fixed in 4% neutral-buffered formalin. Bone samples 
were decalcified, embedded in paraffin, cut into 10-micron 
thick sections and stained with hematoxylin and eosin 
(H&E).
Colon samples were embedded in paraffin and 
then processed into 5 mm sections for H&E staining 
(Fisher Scientific). Crypt depth was analyzed by a BX51 
microscope (Olympus) equipped with a digital camera and 
images acquired using a 10× objective. The images were 
analyzed using ImageJ software. 
Serum cytokine evaluation
Mouse serum was obtained from peripheral blood 
96 h post-irradiation. Circulating cytokine levels were 
determined by Mouse Th1/Th2 10 plex FlowCytomix 
Multiplex kit according to the manufacturer’s protocols 
(eBioscience).
Macrophage cytokine secretion
The RAW 264.7 macrophage cell line was employed 
in this study. The cells were irradiated (5 Gy) in the presence 
and absence of PIF (200 nM). Cytokines TNF-, IL-6, and IL-
10 secretion were analyzed at 48 h of culture using an ELISA 
kit and confirmed by PCR. (ThermoFisher Scientific).
Macrophage isolation and differentiation
Peritoneal macrophages for cell culture 
differentiation studies were obtained by injecting 
intraperitoneally 1 ml of 3% Thioglycollate medium 
(Difco). Four days later, mice were sacrificed and 
peritoneal macrophages were collected from the 
abdominal cavity by washing with 5 ml PBS. Cells 
(1.4 × 106 cells/ml) were dispensed onto 6-well plates 
(Corning Costar) and incubated at 37°C in 5% CO2 for 
75 minutes. Non-adherent cells were discarded and RPMI-
1640 (Gibco) containing 10% fetal calf serum (Biological 
Industries) was added. For M1 differentiation, 10 ng/ml 
GM-CSF and 10 ng/ml LPS (PeprotTech) were added to 
the culture medium followed by incubation at 37°C in 5% 
CO2 for 20 h. Alternatively, for M2 differentiation, 10 ng/
ml M-CSF and 10 ng/ml IL-4 (PeprotTech) were added to 
the medium. [56] 200 nM PIF were added to the medium 
together with the differentiation factors. 
Real-time PCR analysis
Total colonic RNA was extracted using RNeasy® 
Mini Kit columns (QIAGEN) according to the 
manufacturer’s protocol. 1 µg of total RNA was used 
to synthesize cDNA using High-Capacity cDNA kits 
(Applied Biosystems) according to manufacturer’s 
instructions. Detection of transcript levels of B7H1 and 
NOS2, was performed using the TaqMan Gene Expression 
Assay Kit (Applied Biosystems). HPRT-1 was used as a 
housekeeping gene transcript to normalize endogenous 
control. All primers were purchased from Applied 
Biosystems. Real-Time PCR reaction was carried out 
using the ABI Prism 7900 Sequence system (Applied 
Biosystems). Data were analyzed by StepOne Software 
version 2.2 (Applied Biosystems). The analysis of gene 
expression was calculated via a non-parametric Mann-
Whitney U Test. p < 0.05 was considered significant.
GI gene array
30 mg of jejunum tissue was excised and 
homogenized in a Fastprep 120 tissue homogenizer (30 s 
at 4.0 m/sec) in cell lysis buffer (Qiagen). Total RNA 
was extracted from cells using PureLink RNA Mini 
Kits (Ambion). Total RNA (250 ng) was amplified into 
cRNA using TotalPrep RNA amplification kits (Ambion) 
following manufacture’s instruction. After amplification, 
1.5 µg of cRNA was mixed with the hybridization controls 
and it was hybridized to MouseRef-8 array (Illumina). 
The array was hybridized for 16 h in a hybridization oven 
with a rocking platform at 58°C. The array chip then went 
through a series of washes before it was stained with 
streptavidin-Cy3. After the staining, it went through a 
final wash and drying. The array was scanned using the 
Illumina HiScan Scanner.
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Analysis of illumina gene array data
The raw hybridization data were processed using 
R with the Bioconductor lumi package. Data were first 
variance stabilized and then normalized using robust 
spline normalization. Both of these operations are used 
as implemented in the lumi package. Differential gene 
expression between all pairs of sample groups – i.e. 
radiation vs control, radiation with PIF treatment vs. 
control and radiation vs radiation with PIF treatment – was 
calculated using the moderated t-test as implemented in 
the Bioconductor limma package.
Pathway analysis
The output of the limma analysis was used to 
perform gene set enrichment analysis (GSEA) using the 
SetRank method. The key principle of this algorithm is 
that it discards gene sets that have initially been flagged as 
significant, if their significance is only due to the overlap 
with another gene set. It calculates the p-value of a gene 
set using the ranking of its genes in the ordered list of 
p-values as calculated by limma. The following databases 
were searched for significant gene sets: BIOCYC. [57], 
Gene Ontology [58], ITFP [59], KEGG [60], LIPID 
MAPS [52], PhosphoSitePlus [53], REACTOME [61], 
and WikiPathways [62].
For the Heatmap the color scale indicates the relative 
rank of pathway in a given comparison, with 1.0 meaning 
top rank and 0.0 indicating a pathway that was not found 
significant at all. For the gene set network analysis every 
node represents a gene set. The size of a node reflects 
the number of genes in a gene set; the node color reflects 
the significance (corrected p-value) with lower p-values 
having a red color. Edges denote overlap (i.e. one or more 
shared genes) between two gene sets. The width of an 
edge reflects the relative size of the intersection (Jaccard 
similarity) compared to both gene sets. Edges pointed one 
way denote relationships where subtracting one gene set 
from a second reduces the significance of the latter. In this 
case, the arrow points towards the more significant gene 
set. Bidirectional edges indicate subset relations; double 
lines indicate cases where the significance of both gene 
sets is solely due to the intersection between these.
Statistical analysis
Data from the 2 h post- 8 Gy lethal studies are 
described as mean values where the detailed individual 
values (WBC subtypes, RBC details and platelet count) 
are provided in the supplement section at every time 
point. Data from the remainder of the in vivo studies are 
represented as mean ± SEM. Data from in vitro studies 
are represented as mean ± SD. Single comparisons to 
control were made using two-tailed Student’s t-test or 
Mann-Whitney test. One-way repeated measures ANOVA 
followed by Bonferroni’s Multiple Comparison was used 
for data analysis, p < 0.05 was considered to be statistically 
significant. Ileum global gene analysis was carried out 
using heatmap followed by individual genes determining 
differences among the groups setting p < 0.05 as significant.
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